BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 44 filers reported holding BIOXCEL THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,517 | -60.6% | 17,991 | +3.8% | 0.00% | -63.6% |
| Q2 2023 | $115,385 | -64.3% | 17,325 | 0.0% | 0.01% | -71.1% |
| Q1 2023 | $323,285 | +10.0% | 17,325 | +23.1% | 0.04% | +18.8% |
| Q1 2022 | $294,000 | +2.8% | 14,075 | 0.0% | 0.03% | -5.9% |
| Q4 2021 | $286,000 | -41.8% | 14,075 | -13.0% | 0.03% | -45.2% |
| Q3 2021 | $491,000 | +2.9% | 16,175 | -1.5% | 0.06% | +3.3% |
| Q2 2021 | $477,000 | -33.4% | 16,425 | -1.1% | 0.06% | -40.6% |
| Q1 2021 | $716,000 | -1.9% | 16,600 | +5.1% | 0.10% | -6.5% |
| Q4 2020 | $730,000 | +23.7% | 15,800 | +16.2% | 0.11% | -2.7% |
| Q3 2020 | $590,000 | -16.3% | 13,600 | +2.3% | 0.11% | -22.4% |
| Q2 2020 | $705,000 | +120.3% | 13,300 | -7.0% | 0.14% | +83.3% |
| Q1 2020 | $320,000 | +814.3% | 14,300 | +186.0% | 0.08% | +680.0% |
| Q3 2019 | $35,000 | -34.0% | 5,000 | 0.0% | 0.01% | -37.5% |
| Q2 2019 | $53,000 | – | 5,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| APIS CAPITAL ADVISORS, LLC | 40,000 | $836,000 | 1.01% |
| ACT CAPITAL MANAGEMENT, LLC | 20,000 | $418,000 | 0.44% |
| Knoll Capital Management, LLC | 20,000 | $418,000 | 0.26% |
| Artemis Investment Management LLP | 1,428,228 | $29,855,000 | 0.24% |
| Rubric Capital Management LP | 268,528 | $5,615,000 | 0.20% |
| Virtus ETF Advisers LLC | 7,713 | $161,000 | 0.07% |
| BOOTHBAY FUND MANAGEMENT, LLC | 107,700 | $2,252,000 | 0.05% |
| PDT Partners, LLC | 28,031 | $586,000 | 0.05% |
| AllSquare Wealth Management LLC | 3,162 | $66,000 | 0.04% |
| Hennion & Walsh Asset Management, Inc. | 35,221 | $736,000 | 0.04% |